Cardiovasc Prev Pharmacother.  2025 Apr;7(2):55-60. 10.36011/cpp.2025.7.e7.

The connection between diabetes mellitus and stroke: a brief review

• Noh J

• KMID: 2567383
• DOI: http://doi.org/10.36011/cpp.2025.7.e7

Abstract

Stroke is one of the major macrovascular complications of diabetes and increases morbidity and mortality. Hyperglycemia contributes to a heightened risk of stroke incidence. Moreover, people with diabetes may have poorer post-stroke outcomes and higher risk of stroke recurrence than those without diabetes. Recent cardiovascular outcome trials of some antidiabetic medications have shown beneficial effects on stroke prevention. Prevention and improving outcomes of stroke in patients with diabetes requires proper management of hyperglycemia and additional risk factors. This review is an evidence-based approach to epidemiology of stroke in diabetes, the role of glycemic control, and antidiabetic medications in stroke prevention in patients with diabetes mellitus.

Keyword

Diabetes mellitus; Stroke; Glycemic control; Anti-hypoglycemic medication

Reference

1. Park JH, Ha KH, Kim BY, Lee JH, Kim DJ. Trends in cardiovascular complications and mortality among patients with diabetes in South Korea. Diabetes Metab J. 2021; 45:120–4. DOI: 10.4093/dmj.2020.0175. PMID: 33290647.

2. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia. 2006; 49:2859–65. DOI: 10.1007/s00125-006-0493-z. PMID: 17072582.

3. Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, et al. Executive summary of stroke statistics in Korea 2018: a report from the Epidemiology Research Council of the Korean Stroke Society. J Stroke. 2019; 21:42–59. DOI: 10.5853/jos.2018.03125. PMID: 30558400.

4. Liao CC, Shih CC, Yeh CC, Chang YC, Hu CJ, Lin JG, et al. Impact of diabetes on stroke risk and outcomes: two nationwide retrospective cohort studies. Medicine (Baltimore). 2015; 94:e2282. DOI: 10.1097/md.0000000000002282. PMID: 26717365.

5. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014; 383:1973–80. DOI: 10.1016/s0140-6736(14)60040-4. PMID: 24613026.

6. Stahl CH, Lind M, Svensson AM, Gudbjornsdottir S, Martensson A, Rosengren A. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med. 2017; 281:261–72. DOI: 10.1111/joim.12572. PMID: 27925333.

7. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ. 2012; 344:e3564. DOI: 10.1136/bmj.e3564. PMID: 22677795.

8. Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 2019; 10:780–92. DOI: 10.1111/jdi.12932. PMID: 30220102.

9. Echouffo-Tcheugui JB, Xu H, Matsouaka RA, Xian Y, Schwamm LH, Smith EE, et al. Diabetes and long-term outcomes of ischaemic stroke: findings from Get with the Guidelines-Stroke. Eur Heart J. 2018; 39:2376–86. DOI: 10.1093/eurheartj/ehy036. PMID: 29438515.

10. Olaiya MT, Cadilhac DA, Kim J, Thrift AG, Courten B, Andrew NE, et al. Quality of care and one-year outcomes in patients with diabetes hospitalised for stroke or TIA: a linked registry study. J Stroke Cerebrovasc Dis. 2021; 30:106083. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106083. PMID: 34517297.

11. MacDougal EL, Herman WH, Wing JJ, Morgenstern LB, Lisabeth LD. Diabetes and ischaemic stroke outcome. Diabet Med. 2018; 35:1249–57. DOI: 10.1111/dme.13665. PMID: 29744920.

12. Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016; 1862:915–25. DOI: 10.1016/j.bbadis.2016.01.015.

13. Lo JW, Crawford JD, Samaras K, Desmond DW, Kohler S, Staals J, et al. Association of prediabetes and type 2 diabetes with cognitive function after stroke: a STROKOG Collaboration Study. Stroke. 2020; 51:1640–6. DOI: 10.1161/strokeaha.119.028428.

14. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379:633–44. DOI: 10.1056/nejmoa1800256. PMID: 30110583.

15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–53. DOI: 10.1016/s0140-6736(98)07019-6. PMID: 9742976.

16. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977–86. DOI: 10.1056/nejm199309303291401. PMID: 8366922.

17. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577–89. DOI: 10.1056/nejmoa0806470. PMID: 18784090.

18. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–59. DOI: 10.1056/nejmoa0802743. PMID: 18539917.

19. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560–72. DOI: 10.1056/nejmoa0802987. PMID: 18539916.

20. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129–39. DOI: 10.1016/j.jvs.2009.02.026. PMID: 19092145.

21. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019; 42:416–26. DOI: 10.2337/dc17-1144. PMID: 30104301.

22. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, et al. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019; 43:398–406. DOI: 10.4093/dmj.2019.0137. PMID: 31441247.

23. Hankey GJ, Anderson NE, Ting RD, Veillard AS, Romo M, Wosik M, et al. Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry. 2013; 84:281–7. DOI: 10.1136/jnnp-2012-303365. PMID: 23085934.

24. Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2014; 2014:CD005346. DOI: 10.1002/14651858.cd005346.pub4. PMID: 24453023.

25. Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA. 2019; 322:326–35. DOI: 10.1001/jama.2019.9346. PMID: 31334795.

26. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:870–947. DOI: 10.1161/str.0b013e318284056a. PMID: 23370205.

27. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366:1279–89. DOI: 10.1016/s0140-6736(05)67528-9. PMID: 16214598.

28. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38:865–73. DOI: 10.1161/01.str.0000257974.06317.49. PMID: 17290029.

29. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016; 374:1321–31. DOI: 10.1016/j.jvs.2016.05.060. PMID: 26886418.

30. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834–44. DOI: 10.1056/nejmoa1607141. PMID: 27633186.

31. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394:121–30. DOI: 10.1016/s0140-6736(19)31149-3. PMID: 31189511.

32. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311–22. DOI: 10.1056/nejmoa1603827. PMID: 27295427.

33. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392:1519–29. DOI: 10.1016/s0140-6736(18)32261-x. PMID: 30291013.

34. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381:841–51. DOI: 10.1056/nejmoa1901118. PMID: 31185157.

35. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373:2247–57. DOI: 10.1056/nejmoa1509225. PMID: 26630143.

36. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377:1228–39. DOI: 10.1056/nejmoa1612917. PMID: 28910237.